ArticleAllergy and asthma proceedings2022
The long COVID syndrome: A conundrum for the allergist/immunologist.
Article in Allergy and asthma proceedings, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 14 citations in OpenAlex.
- Vasoprotective effects of lysophosphatidic acid inhibit vascular injury caused by SARS-CoV-2 infection.Scientific reports · 2025Article
- Different polarization and functionality of CD4+ T helper subsets in people with post-COVID condition.Frontiers in immunology · 2024Article
- Symptom flares after COVID-19 infection versus vaccination among youth with PANS/PANDAS.Allergy and asthma proceedings · 2023Article
- The complexities of allergic diseases continue to challenge the allergist-immunologist.Allergy and asthma proceedings · 2023Article
- SARS-CoV-2 Main Protease Targets Host Selenoproteins and Glutathione Biosynthesis for Knockdown via Proteolysis, Potentially Disrupting the Thioredoxin and Glutaredoxin Redox Cycles.Antioxidants (Basel, Switzerland) · 2023Article
- Cellular miR-6741-5p as a Prognostic Biomarker Predicting Length of Hospital Stay among COVID-19 Patients.Viruses · 2022Article
- A confluence of advanced treatment options for atopic dermatitis, eosinophilic lung diseases and chronic urticaria brought about by the revolutionary discovery of biologics and Janus kinase inhibitors.Allergy and asthma proceedings · 2022Article
- Asthma biomarkers and COVID-19 continue to dominate current medical issues.Allergy and asthma proceedings · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.